Skip to main content
HR 2751 117th Congress House Environmental Protection Blood and blood diseases Civil actions and liability Environmental assessment, monitoring, research Environmental health Federal district courts Hazardous wastes and toxic substances Health care costs and insurance Health care coverage and access Health promotion and preventive care Manufacturing Medical research Medical tests and diagnostic methods Pollution liability

PFAS Accountability Act of 2021

Introduced: April 22, 2021 Introduced by: Dean, Madeleine Democratic · Pennsylvania See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 19, 2021
Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.
Apr 23, 2021
Referred to the Subcommittee on Environment and Climate Change.
Apr 22, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 22, 2021
Introduced in House
 Plain-English summary Congressional Research Service

PFAS Accountability Act of 2021

This bill provides a cause of action under the Toxic Substances Control Act for individuals or classes of individuals who were significantly exposed to perfluoroalkyl or polyfluoroalkyl substances, commonly referred to as PFAS. These substances are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing.

Specifically, the bill provides a cause of action those who were significantly exposed to PFAS (or have reasonable grounds to believe they were exposed) against persons who engaged in any portion of a manufacturing process that created the PFAS and foresaw (or reasonably should have foreseen) the creation or use of PFAS would result in human exposure.

The bill authorizes a court to award medical monitoring to claimants if (1) they have been significantly exposed to PFAS, (2) they have an increased risk of developing a disease associated with such exposure, (3) the increased risk provides a reasonable basis to conclude that periodic diagnostic medical examinations is necessary, and (4) the medical examinations are effective in detecting a disease associated with PFAS exposure.

The bill establishes a presumption of significant exposure to PFAS if the claimant (1) provides medical results proving the presence of PFAS in the body, or (2) demonstrates the defendant's manufacturing process created the PFAS to which the claimant was exposed and the PFAS were released into one or more areas where the claimant would have been exposed for at least one year.

What's happening now October 19, 2021

Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.

 Committees of jurisdiction 4
 Cosponsors 5
All 5 Democratic 5